| 摘要 |
Disclosed is a pharmaceutical composition comprising a population of isolated human adult c-kit positive cardiac stem cells and a pharmaceutically acceptable carrier, wherein at least 50% of said isolated cardiac stem cells have immortal DNA. Also disclosed is a substantially pure population of adult cardiac stem cells which are c-kit positive, IGF-1 receptor positive, p16INK4a negative, and have immortal DNA. Further disclosed is a method for isolating adult cardiac stem cells having immortal DNA comprising: (a) exposing adult cardiac stem cells to a DNA label, wherein said cardiac stem cells are c-kit positive and isolated from myocardial tissue; (b) culturing said labelled cardiac stem cells for at least one population doubling; and (c) selecting the cardiac stem cells that are negative for the DNA label, wherein said selected stem cells are cardiac stem cells having immortal DNA. |
